These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9873766)

  • 1. National haemophilia treatment protocols: Canada.
    Teitel JM
    Haemophilia; 1998 Jul; 4(4):422-3. PubMed ID: 9873766
    [No Abstract]   [Full Text] [Related]  

  • 2. Guidelines on treatment of haemophilia in Sweden.
    Berntorp E
    Haemophilia; 1998 Jul; 4(4):425-6. PubMed ID: 9873768
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment protocol of haemophilia and other congenital bleeding disorders in Italy. Italian Association of Hemophilia Centers (AICE).
    Gringeri A
    Haemophilia; 1998 Jul; 4(4):423-4. PubMed ID: 9873767
    [No Abstract]   [Full Text] [Related]  

  • 4. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 5. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Issues in making a therapeutic choice: recombinant and/or human-derived products.
    Aledort LM
    Haemophilia; 2001 Jan; 7(1):89-90. PubMed ID: 11136386
    [No Abstract]   [Full Text] [Related]  

  • 7. Recombinant clotting factors in the treatment of hemophilia.
    Lee C
    Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
    [No Abstract]   [Full Text] [Related]  

  • 8. Sodium content in products used to treat haemophilia.
    Altisent C; Martorell M; de la Sierra A
    Haemophilia; 2016 Jul; 22(4):e324-7. PubMed ID: 27228069
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 10. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment protocols in The Netherlands.
    Mauser-Bunschoten EP; Roosendaal G; van den Berg HM
    Haemophilia; 1998 Jul; 4(4):428-30. PubMed ID: 9873770
    [No Abstract]   [Full Text] [Related]  

  • 12. Prophylaxis in patients with haemophilia: introduction.
    Chambost H
    Haemophilia; 2010 Mar; 16 Suppl 2():1-3. PubMed ID: 20132331
    [No Abstract]   [Full Text] [Related]  

  • 13. Switching to extended half-life products in Canada - preliminary data.
    Keepanasseril A; Stoffman J; Bouskill V; Carcao M; Iorio A; Jackson S;
    Haemophilia; 2017 Jul; 23(4):e365-e367. PubMed ID: 28548284
    [No Abstract]   [Full Text] [Related]  

  • 14. The modern treatment of haemophilia: a narrative review.
    Franchini M
    Blood Transfus; 2013 Apr; 11(2):178-82. PubMed ID: 22790275
    [No Abstract]   [Full Text] [Related]  

  • 15. Recombinant clotting factor concentrates.
    Lusher JM
    Baillieres Clin Haematol; 1996 Jun; 9(2):291-303. PubMed ID: 8800506
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of haemophilia.
    Lancet; 1973 Sep; 2(7830):648-9. PubMed ID: 4125623
    [No Abstract]   [Full Text] [Related]  

  • 17. Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B.
    Rayment R; Chalmers E; Forsyth K; Gooding R; Kelly AM; Shapiro S; Talks K; Tunstall O; Biss T;
    Br J Haematol; 2020 Sep; 190(5):684-695. PubMed ID: 32390158
    [No Abstract]   [Full Text] [Related]  

  • 18. Who should receive recombinant factor VIII?
    Giangrande PL
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S25-7. PubMed ID: 9351533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis.
    Carcao M; Lambert T; Leissinger C; Escuriola-Ettingshausen C; Santagostino E; Aledort L;
    Haemophilia; 2018 Nov; 24(6):845-848. PubMed ID: 29989273
    [No Abstract]   [Full Text] [Related]  

  • 20. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
    Goldstein B; Geldziler B; Bjerre J; Seremetis S
    Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.